KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Boston Scientific (BSX) Equity Ratio (2016 - 2025)

Boston Scientific's Equity Ratio history spans 17 years, with the latest figure at 0.56 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 1.4% year-over-year to 0.56; the TTM value through Dec 2025 reached 0.56, up 1.4%, while the annual FY2025 figure was 0.56, 1.4% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.56 at Boston Scientific, up from 0.01 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.62 in Q4 2022 and bottomed at 0.07 in Q4 2021.
  • The 5-year median for Equity Ratio is 0.52 (2021), against an average of 0.3.
  • The largest annual shift saw Equity Ratio tumbled 110.89% in 2021 before it surged 994.67% in 2022.
  • A 5-year view of Equity Ratio shows it stood at 0.07 in 2021, then skyrocketed by 994.67% to 0.62 in 2022, then decreased by 11.05% to 0.56 in 2023, then dropped by 0.58% to 0.55 in 2024, then rose by 1.4% to 0.56 in 2025.
  • Per Business Quant, the three most recent readings for BSX's Equity Ratio are 0.56 (Q4 2025), 0.01 (Q2 2025), and 0.0 (Q1 2025).